HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Q2: Anti-Japanese Sentiment Sinks SK-II Sales As Late Cough/Cold Season Weighs On Health

Executive Summary

P&G reports Chinese consumer backlash against Japanese brands over Fukushima nuclear facility wastewater disposal, combined with ‘soft market conditions,’ led to a mid-single-digit decline in organic sales for P&G’s skin and personal-care products in the fiscal second quarter.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Q4 Beauty Earnings Preview: China Volatility In 2023 Has Analysts Leery Of Big Beauty’s Results

Shiseido, L’Oreal and The Estee Lauder Companies are preparing to announce earnings results for the final three months of 2023, and all are expected to report headwinds that held back performance in China. Analysts anticipate a strong fourth quarter from Coty, which has been largely insulated from the ups and downs of the Chinese market in recent years.

P&G Prepares For Growth To Move From Price Increases To Volume As It Girds For FX Headwind

Contribution of price increases to P&G’s organic sales growth will decrease 3 to 4 points during its FY2024 while volume will “progress sequentially,” says CFO Andre Schulten during firm’s first-quarter earnings briefing. Net sales up 6% to $21.9bn in July-September.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154355

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel